While investigating the role of p38 MAPK in regulating melanogenesis, we found that pyridinyl imidazole inhibitors class compounds as well as the analog compound SB202474, which does not inhibit p38 MAPK, suppressed both α-MSH-induced melanogenesis and spontaneous melanin synthesis. In this study, we demonstrated that the inhibitory activity of the pyridinyl imidazoles correlates with inhibition of the canonical Wnt/β-catenin pathway activity. Imidazole-treated cells showed a reduction in the level of Tcf/Lef target genes involved in the β-catenin signaling network, including ubiquitous genes such as Axin2, Lef1, and Wisp1 as well as cell lineage-restricted genes such as microphthalmia-associated transcription factor and dopachrome tautomerase. Although over-expression of the Wnt signaling pathway effector β-catenin slightly restored the melanogenic program, the lack of complete reversion suggested that the imidazoles interfered with β-catenin-dependent transcriptional activity rather than with β-catenin expression. Accordingly, we did not observe any significant change in β-catenin protein expression. The independence of p38 MAPK activity from the repression of Wnt/β-catenin signaling pathway was confirmed by small interfering RNA knockdown of p38 MAPK expression, which by contrast, stimulated β-catenin-driven gene expression. Our data demonstrate that the small molecule pyridinyl imidazoles possess two distinct and opposite mechanisms that modulate β-catenin dependent transcription: a p38 inhibition-dependent effect that stimulates the Wnt pathway by increasing β-catenin protein expression and an off-target mechanism that inhibits the pathway by repressing β-catenin protein functionality. The p38-independent effect seems to be dominant and, at least in B16-F0 cells, results in a strong block of the Wnt/β-catenin signaling pathway.
References
[1]
Costin GE, Hearing VJ (2007) Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB 21: 976–994.
[2]
Miyamura Y, Coelho SG, Wolber R, Miller SA, Wakamatsu K, et al. (2007) Regulation of human skin pigmentation and responses to ultraviolet radiation. Pigment Cell Res 20: 2–13.
[3]
Winder A, Kobayashi T, Tsukamoto K, Urabe K, Aroca P, et al. (1994) The tyrosinase gene family-interactions of melanogenic proteins to regulate. Cell Mol Biol Res 40: 613–626.
[4]
Land EJ, Ramsden CA, Riley PA (2004) Quinone chemistry and melanogenesis. Methods Enzymol 378: 88–109.
[5]
Hearing VJ, Tsukamoto K (1991) Enzymatic control of pigmentation in mammals. FASEB 5: 2902–2909.
[6]
Slominski A, Tobin DJ, Shibahara S, Wortsman J (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155–1228.
[7]
Slominski A (2009) Neuroendocrine activity of the melanocyte. Exp Dermatol 18: 760–763.
[8]
Yasumoto K, Yokohama K, Takahashi K, Tomita Y, Shibahara S (1997) Functional analysis of microphthalmia-associated transcription factor in pigment cell-specific traanscription of the human tyrosinase family genes. J Biol Chem 272: 503–509.
[9]
Bertolotto C, Bille K, Ortonne JP, Ballotti R (1998) In B16 melanoma cells, the inhibition of melanogenesis by TPA results from PKC activation and diminution of microphthalmia binding to the M-box of the tyrosinase promoter. Oncogene 16: 1665–1670.
[10]
Bertolotto C, Buscà R, Abbe P, Bille K, Aberdam E, et al. (1998) Different cis-acting elements are involved in the regulation of TRP1 and TRP2 promoter activities by cycling AMP: pivotal role of M boxes () and of microphthalmia. Mol Cell Biol 18: 694–702.
[11]
Hachiya A, Kobayashi A, Yoshida Y, Kitahara T, Takema Y, et al. (2004) Biphasic expression of two paracrine melanogenic cytokines, stem cell factor and endothelin-1, in ultraviolet B-induced human melanogenesis. Am J Pathol 165: 2099–2109.
[12]
Slominski A, Tobin DJ, Shibahara S, Wortsman J (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155–1228.
[13]
Wu J, Saint-Jeannet JP, Klein PS (2003) Wnt-frizzled signaling in neural crest formation. Trends Neurosci 26: 40–45.
[14]
Ikeya M, Lee SM, Johnson JE, McMahon AP, Takada S (1997) Wnt signalling requie for expansion of neural crest and CNS progenitors. Nature 389: 966–970.
[15]
Bellei B, Pitisci A, Catricalà C, Larue L, Picardo M (2011) Wnt/β-catenin signalling is stimulated by α-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation. Pigment Cell Melanoma Res 24: 309–325.
[16]
Schepsky A, Bruser K, Gunnarsson GJ, Goodall J, Hallsson JH, et al. (2006) The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. Mol Cell Biol 26: 8914–8927.
[17]
Peifer M, Polakis P (2000) Wnt signaling in oncogenesis and embryogenesis- a look outside the nucleus. Science 287: 1606–1609.
[18]
Behrens J, von Kries JP, Kühl M, Bruhn L, Wdlich D, et al. (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382: 638–642.
[19]
Jin T, George Fantus I, Sun J (2008) Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal 20: 1697–1704.
[20]
Shitashige M, Hirohashi S, Yamada T (2008) Wnt signaling inside the nucleus. Cancer Sci 99: 631–637.
[21]
Kikuchi A, Kishida S, Yamamoto H (2006) Regulation of Wnt signaling by protein-protein interaction and post-translational midifications. Exp Mol Med 38: 1–10.
[22]
Daugherty RL, Gottardi CJ (2007) Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology 22: 303–309.
[23]
Hino S, Tanji C, Nakayama KI, KIkuchi A (2005) Phosphorylation of beta-catenin by cycling AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitinations. Mol Cell Biol 25: 9063–9072.
[24]
van Veelen W, Le NH, Helvensteinijn W, Blonden L, Theeuwes M, et al. (2011) β-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 60: 1204–1212.
[25]
Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, et al. (2011) Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 24: 631–642.
[26]
Lepourcelet M, Chen YN, France DS, Wang H, Crews P, et al. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5: 91–102.
[27]
McMillan M, Kahn M (2005) Investigating Wnt signaling: a chemogenomic safari. Drug Discov Today 10: 1467–1474.
[28]
Eguchi M, Nguyen C, Lee SC, Kahn M (2005) ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem 1: 467–472.
[29]
Ma H, Naguyen C, Lee KS, Kahn M (2005) Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated servivi gene expression. Oncogene 24: 3619–3631.
[30]
Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, et al. (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat Chem Biol 6: 829–236.
[31]
Biechele TL, Camp ND, Fass DM, Kulikauskas RM, Robin NC, et al. (2010) Chemical-genetic screen identifies riluzole a san enhancer of Wnt/β-catenin signaling in melanoma. Chem Biol 17: 1177–1182.
[32]
Widlund HR, Horstmann MA, Prince ER, Cui J, Lessnick SL, et al. (2002) Beta-catenin-indiced melanoma growth requie the downstream target Microphthalmia-associated transcription factor. J Cell Biol 158: 1079–1087.
[33]
Yamaguchi Y, Itami S, Watabe H, Yasumoto K, Abdel-Malek ZA, et al. (2004) Mesenchymal-epithelial interactions in the skin: increate expression of dickkopf1 by palmoplantar fibroblasto inhibits melanocyte growth and differentiation. J Cell Biol 165: 275–285.
[34]
Yamaguchi Y, Passeron T, Watabe H, Yasumoto K, Rouzaud F, et al. (2007) The effects of dikkopf1 on gene expression and Wnt signaling by melanocytes: mechanisms underlying its suppression of melanocyte function and proliferation. J Invest Dermatol 127: 1217–1225.
[35]
Kim DS, Park SH, Kwon SB, Na JI, Huh CH, et al. (2007) Additive effects of heat and p38 MAPK inhibitor treatment on melanin synthesis. Arch Pharm Res 305: 581–586.
[36]
Singh SK, Sarkar C, Mallick S, Saha B, Bera R, et al. (2005) Human placental lipid induces melanogenesis through p38 MAPK in B16F10 mouse melanoma. Pigment Cell Res 18: 113–21.
[37]
Birkenkamp KU, Tuyt LM, Lummen C, Wierenga AT, Kruijer W, et al. (2000) The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect the ERK pathway. Br J Pharmacol 131: 99–107.
[38]
Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, et al. (2002) Inhibition of nucleoside tran sport by p38 MAPK inhibitors. J Biol Chem 277: 28364–28367.
[39]
Shibazaki M, Takeuchi T, Ahmed S, Kikuchi H (2004) Suppression by p38 MAP kinase inhibitors (pyridinyl imidazolo compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the possible mechanism. J Biol Chem 279: 3869–3876.
[40]
Shanware NP, Williams LM, Bowler MJ, Tibbetts RS (2009) Non-specific in vivo inhibition of CK1 by the pyridinyl imidazolo p38 inhibitors SB 203580 and SB 202190. BMB Rep 42: 142–147.
[41]
Menon MB, Kotlyarov A, Gaestel M (2011) SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition. PLoS One 6: e23054.
[42]
Bellei B, Maresca V, Flori E, Pitisci A, Larue L, et al. (2010) p38 regulates pigmentation via proteasomal degradation of tyrosinase. J Biol Chem 285: 7288–7299.
[43]
Medrano EE, Yang F, Boissy R, Farooqui J, Shah V, et al. (1994) Terminal differentiation and senescence in the human melanocyte: repression of tyrosine-phosphorylation of the extracellular signal-regulated kinase 2 selectively defines the two phenotypes. Mol Biol Cell 5: 497–509.
[44]
Gonzales GA, Montminy MR (1989) Cyclic AMP stimulates somatostatin gene transcription by phosphorylation by CREB at erine 133. Cell 59: 675–680.
[45]
Chrivia JC, Kwok RPS, Lamb N, Hagiwara M, Montminy RM, Goodman RH (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365: 855–859.
[46]
Huber WE, Price ER, Widlund HR, Du J, Davis IJ, et al. (2003) A tissue-restricted cAMP transcriptional response SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of micropht.
[47]
Saito H, Yasumoto K, Takeda K, Takahashi K, Fukuzaki A, et al. (2002) Melanocyte-specific microphthalmia-associated transcription factor isoform activates its own gene promoter through physycal interaction with lymphoid-enhancing factor 1. J Biol Chem 277: 28787–28794.
[48]
Watanabe A, Takeda K, Ploplis B, Tachibana M (1998) Epistatic relationship between Waardenburg syndrome genes MITF and PAX3. Nat Genet 18: 283–286.
[49]
Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E, et al. (2000) Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet 9: 1907–1917.
[50]
Takeda K, Yasumoto K, Takada R, Takada S, Watanabe K, et al. (2000) Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J Biol Chem 275: 14013–14016.
[51]
Bikkavilli RK, Feigin ME, Malbon CC (2008) p38 mitogen.activated protein kinase regulates canonical Wnt-beta-catenin signaling by inactivation of GSK3beta. J Cell Sci 121: 3598–3607.
[52]
？ervenka I, Wolf J, Ma？ek J, Krejci P, Wilcox WR, et al. (2011) Mitogen-activated protein kinases promote WNT/beta-catenin signaling via phosphorylation of LRP6. Mol Cell Biol 31: 179–189.
[53]
Verkaar F, van der Doelen AA, Snmits JF, Blakesteijn WM, Zaman GJ (2011) Inhibition of Wnt/β-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Iδ/ε. Chem Biol 18: 485–494.
[54]
Ho AK, Prince L, Mackova M, Chik CL (2001) Potentiation of cyclic AMP and cyclic GMP accumulation by p38 mitogen-activated protein kinase (p38MAPK) inhibitors in rat pinealocytes. Biochem Pharmacol 62: 1605–1611.
[55]
Bain J, Plater L, Elliott M, Shpiro N, Hastie J, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297–315.
[56]
Bellei B, Flori E, Izzo E, Maresca V, Picardo M (2008) GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signal 20: 1750–1761.
[57]
Takahashi-Yanaga F, Kahn M (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153–3162.
[58]
Teo JL, Kahn M (2010) The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. Adv Drug Deliv Rev 62: 1149–1155.
[59]
Shibazaki M, Takeuchi T, Ahmed S, Kikuchi H (2004) Suppression by p38 MAP kinase inhibitors (pyridinyl imidazolo compunds) of Ah receptor target gene activaation by 2,3,7,8-tetracholorodibenzo-p-dioxin and the possible mechanism. J Biol Chem 279: 3869–3876.
[60]
Dickinson LA, Gulizia RJ, Trauger JW, Baird EE, Mosier DE, et al. (1998) Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc Natl Acad Sci U S A 95: 12890–12895.
[61]
Supekova L, Pezacki JP, Su AI, Loweth CJ, Riedl R, et al. (2002) Genomic effects of polyamide/DNA interactions on mRNA expression. Chem Biol 9: 821–827.
[62]
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage serviva oncogene amplified in malignant melanoma. Nature 436: 117–122.
